Deciphering the suppressive effects of CBX8 on prostate cancer cell invasion

doi:10.3969/j.issn.1674-8115.2023.12.005

Abstract

Abstract:

Objective ·To elucidate the regulatory mechanisms of the chromobox protein homolog 8 (CBX8) in prostate cancer metastasis from transcriptome and epigenetic modification perspectives. Methods ·The correlation between the expression of CBX proteins and prostate adenocarcinoma (PRAD) in The Cancer Genome Atlas (TCGA) was examined through an analysis based on cBioPortal database. A stable CBX8 knockdown DU145 prostate cancer cell line was established via short hairpin RNA (shRNA) transfection. Subsequently, the proliferation and invasion of the CBX8 knockdown cells were analyzed by CCK-8 assay and Transwell assay, respectively. Transcriptome changes of the CBX8 knockdown cells were investigated through RNA sequencing (RNA-seq) coupled with Gene Set Enrichment Analysis (GSEA). To further evaluate the functional implications of these transcriptomic alterations, Gene Ontology (GO) for functional analysis was deployed. Moreover, to identify potentially affected signalling pathways, the Kyoto Encyclopedia of Genes and Genomes (KEGG) was utilized for pathway enrichment analysis. Lastly, the levels of H3K27me3, a key histone modification associated with CBX8, in the knockdown cells were determined by chromatin immunoprecipitation sequencing (ChIP-seq). Results ·Bioinformatic analysis with cBioPortal database, based on TCGA-PRAD cohorts, unveiled a high CBX8 mRNA expression in PRAD. Knockdown of CBX8 did not significantly affect the proliferation of DU145 cells (P>0.05), but caused a a significant increase in their invasiveness (P<0.05). The RNA-seq analysis revealed that CBX8 knockdown led to the upregulation of 750 genes and the downregulation of 951 genes. Notably, branched-chain-amino-acid aminotransferase 1 (BCAT1), a gene implicated in the metastasis of various types of cancers, showed a significant increase in expression following CBX8 knockdown. GSEA showed that the expression levels were of the affected genes were related to the functions of the polycomb repressive complex 1 (PRC1). A further investigation using GO and KEGG analyses identified several enriched pathways in the CBX8 knockdown cells, including transfer RNA (tRNA) aminoacylation, DNA replication, changes in aminoacyl-tRNA ligase activity, and cadherin binding. Interestingly, in terms of cell component of GO functional analysis, cell-substrate junction-related genes associated with tumor metastasis appeared to be enriched. ChIP-seq results showed a global decrease in H3K27me3 levels. Significantly, 97 reduced H3K27me3 peaks were found located nearby genes that were upregulated upon CBX8 knockdown, including the transcriptional start site of BCAT1. Conclusion ·CBX8 is highly expressed in prostate cancer. CBX8 suppresses prostate cancer cell invasion, possibly by recruiting the transcriptional repressive PRC1 complex to the transcription site of BCAT1, thereby inhibiting BCAT1 transcription and tumor metastasis.

Key words: chromobox protein homolog 8 (CBX8), prostate cancer, cell proliferation, tumor invasion

CLC Number:

YANG Wanli, SONG Juan, LI Bing, LAO Yimin. Deciphering the suppressive effects of CBX8 on prostate cancer cell invasion[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(12): 1507-1519.

Figures/Tables 5

Fig 1 Expression levels of mRNA and mutations of CBX family in prostate cancer

Fig 2 Effects of knocking down of CBX8 on the proliferation and invasion ability of prostate cancer cells

Fig 3 Gene expression profiling and GSEA of CBX8 knocking down prostate cancer cells

Fig 4 Functional annotation and enrichment analysis of differentially expressed genes in CBX8 knocking down prostate cancer cells

Fig 5 Effect of CBX8 knocking down on H3K27me3 modification in prostate cancer cells

TrendMD

References 36

1	ZHANG S W, SUN K X, ZHENG R S, et al. Cancer incidence and mortality in China, 2015[J]. J Natl Cancer Cent, 2021, 1(1): 2-11.
2	GERSTBERGER S, JIANG Q W, GANESH K. Metastasis[J]. Cell, 2023, 186(8): 1564-1579.
3	PIUNTI A, SHILATIFARD A. The roles of Polycomb repressive complexes in mammalian development and cancer[J]. Nat Rev Mol Cell Biol, 2021, 22(5): 326-345.
4	LAUGESEN A, HØJFELDT J W, HELIN K. Molecular mechanisms directing PRC2 recruitment and H3K27 methylation[J]. Mol Cell, 2019, 74(1): 8-18.
5	SU W J, HAN H H, WANG Y, et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression[J]. Cancer Cell, 2019, 36(2): 139-155.e10.
6	JUNG J, BUISMAN S C, WEERSING E, et al. CBX7 induces self-renewal of human normal and malignant hematopoietic stem and progenitor cells by canonical and non-canonical interactions[J]. Cell Rep, 2019, 26(7): 1906-1918.e8.
7	KLAUKE K, RADULOVIĆ V, BROEKHUIS M, et al. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation[J]. Nat Cell Biol, 2013, 15(4): 353-362.
8	DEL GAUDIO N, DI COSTANZO A, LIU N Q, et al. CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway[J]. Mol Cancer, 2022, 21(1): 125.
9	HU F F, CHEN H, DUAN Y, et al. CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma[J]. Mol Ther Nucleic Acids, 2021, 27: 670-684.
10	WANG X, QIN G, LIANG X T, et al. Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma[J]. Nat Commun, 2020, 11(1): 1141.
11	ZHANG C Z, CHEN S L, WANG C H, et al. CBX8 exhibits oncogenic activity via AKT/β-catenin activation in hepatocellular carcinoma[J]. Cancer Res, 2018, 78(1): 51-63.
12	MENG Q C, LI L, WANG L P. High CBX8 expression leads to poor prognosis in laryngeal squamous cell carcinoma by inducing EMT by activating the Wnt/β-catenin signaling pathway[J]. Front Oncol, 2022, 12: 881262.
13	DENG H L, GUAN X W, GONG L C, et al. CBX6 is negatively regulated by EZH2 and plays a potential tumor suppressor role in breast cancer[J]. Sci Rep, 2019, 9(1): 197.
14	HUANG Z N, YAN Y L, ZHU Z, et al. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling[J]. Cell Death Dis, 2021, 12(6): 537.
15	BERNARD D, MARTINEZ-LEAL J F, RIZZO S, et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus[J]. Oncogene, 2005, 24(36): 5543-5551.
16	FORZATI F, FEDERICO A, PALLANTE P, et al. CBX7 is a tumor suppressor in mice and humans[J]. J Clin Invest, 2012, 122(2): 612-623.
17	ZHANG Y, KANG M, ZHANG B, et al. m⁶A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5[J]. Mol Cancer, 2019, 18(1): 185.
18	WANG G, TANG J J, ZHAN W X, et al. CBX8 suppresses tumor metastasis via repressing snail in esophageal squamous cell carcinoma[J]. Theranostics, 2017, 7(14): 3478-3488.
19	CONNELLY K E, WEAVER T M, ALPSOY A, et al. Engagement of DNA and H3K27me3 by the CBX8 chromodomain drives chromatin association[J]. Nucleic Acids Res, 2019, 47(5): 2289-2305.
20	CERAMI E, GAO J J, DOGRUSOZ U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404.
21	SUBRAMANIAN A, TAMAYO P, MOOTHA V K, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci USA, 2005, 102(43): 15545-15550.
22	LIBERZON A, BIRGER C, THORVALDSDÓTTIR H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection[J]. Cell Syst, 2015, 1(6): 417-425.
23	MAO L, CHEN J, LU X, et al. Proteomic analysis of lung cancer cells reveals a critical role of BCAT1 in cancer cell metastasis[J]. Theranostics, 2021, 11(19): 9705-9720.
24	XU M, LIU Q Q, JIA Y L, et al. BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma[J]. Oncol Lett, 2016, 12(4): 2648-2656.
25	TANG J J, WANG G, ZHANG M F, et al. Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer[J]. Oncotarget, 2014, 5(21): 10778-10790.
26	SHANG S, YANG Y W, CHEN F, et al. TRIB3 reduces CD8⁺ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer[J]. Sci Transl Med, 2022, 14(626): eabf0992.
27	JIANG Q, LI J, WANG J Y, et al. Inhibition of CDKL3 downregulates STAT1 thus suppressing prostate cancer development[J]. Cell Death Dis, 2023, 14(3): 189.
28	HATZIIEREMIA S, MOHAMMED Z, MCCALL P, et al. Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence[J]. Mol Carcinog, 2016, 55(11): 1667-1677.
29	KACHROO P, LEE M H, ZHANG L, et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer[J]. J Exp Clin Cancer Res, 2013, 32(1): 97.
30	LERCHENMÜLLER C, HEIßENBERG J, DAMILANO F, et al. S100A6 regulates endothelial cell cycle progression by attenuating antiproliferative signal transducers and activators of transcription 1 signaling[J]. Arterioscler Thromb Vasc Biol, 2016, 36(9): 1854-1867.
31	WANG T, HAN S L, DU G. S100A6 represses Calu-6 lung cancer cells growth via inhibiting cell proliferation, migration, invasion and enhancing apoptosis[J]. Cell Biochem Funct, 2021, 39(6): 771-779.
32	MOUSSA H F, BSTEH D, YELAGANDULA R, et al. Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing[J]. Nat Commun, 2019, 10(1): 1931.
33	MACRAE T A, FOTHERGILL-ROBINSON J, RAMALHO-SANTOS M. Regulation, functions and transmission of bivalent chromatin during mammalian development[J]. Nat Rev Mol Cell Biol, 2023, 24(1): 6-26.
34	TERRANOVA C J, TANG M, MAITITUOHETI M, et al. Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy[J]. Cell Rep, 2021, 36(3): 109410.
35	CHAN H L, BECKEDORFF F, ZHANG Y S, et al. Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms[J]. Nat Commun, 2018, 9(1): 3377.
36	CHUNG C Y, SUN Z, MULLOKANDOV G, et al. Cbx8 acts non-canonically with Wdr5 to promote mammary tumorigenesis[J]. Cell Rep, 2016, 16(2): 472-486.

[1]	YAN Yeqing, LIANG Sheng, YANG Bin, ZOU Renjian, MA Yufei, CAI Lisheng, WANG Hui, FU Hongliang. Role of ¹⁸F-MD-PSMA PET/CT in initial stage of intermediate and high risk prostate cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(7): 873-881.
[2]	CHEN Jin, FU Yao. Research progress in autologous regeneration of human corneal endothelial cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(6): 775-780.
[3]	DING He, CAO Yanglin, HE Yang, WEI Xing, YANG Jianfeng. SMAD7 expression in multiple myeloma and its effect on cell proliferation and drug resistance [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 858-865.
[4]	HU Zhexuan, ZHANG Xin, WO Lulu, LI Jingchi, WANG Jiao, ZHOU Cixiang, ZHAO Qian. Study on the function of TRMT61A in liver cancer cell and its mechanism [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(6): 742-750.
[5]	XU Feixiang, WANG Sheng, XUE Mingming, TONG Chaoyang, CHEN Yumei. Effect of altered expression of long non-coding RNA-B230352I09 on proliferation and cycle of H9C2 cardiomyocytes [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(5): 578-582.
[6]	WANG Hui, ZHAO Ying, WEN Lirong, CAO Jun, YANG Jiping, YUAN Yongming. Diagnostic value of PSA, TAP and MACC1 expression in blood of patients with prostate cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(4): 496-501.
[7]	Ming CHEN, Jing ZHANG. Inhibitory effect of sanguinarine on proliferaton and invasion of gastric cancer cells by upregulating m⁶A methyltransferase 14 [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 135-141.
[8]	Yan-qi HE, Rui CHI, Meng-ping CHEN, Si CHEN, Chun-liang LIU, Yun-xia LIU, Hai-peng SUN. Function of branched-chain amino acid catabolism in lung cancer cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 858-864.
[9]	YAN Yu-qing, SHEN Chao-qin, CHEN Hao-yan, HONG Jie#, WANG Zhen-hua#. Expression of lnc-MTBP-5 in colorectal cancer and its effect on cell invasion [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1193-1201.
[10]	ZHANG Jing. Inhibitory effect of toosendanin on gastric cancer cells BGC-823 by downregulating circDLST [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1202-1206.
[11]	SONG Xu-jia, ZHANG Shi-jun, Lü Wen-xin, HUANG Lin, ZHANG Yan, WU Ming-gui, XIE Shao-wei. Synergistic chemo-photothermal therapy of castration-resistant prostate cancersingle-walled carbon nanotube [J]. , 2020, 40(4): 450-.
[12]	HONG Xi1, LIU Li-jie1, HUANG Xian-yu2, LUO Jing2, YU Jian-jun1. Effects of BRD4 inhibitor on histone crotonylation, proliferation and migration of prostate cancer cells [J]. , 2019, 39(7): 721-.
[13]	XIE Shao-wei,DONG Bai-jun,XIA Jian-guo,WANG Yan-qing,LI Hong-li,ZHANG Shi-jun,YANG Wen-qi,LI Feng-hua. Value of prostate anterior horn biopsy in the diagnosis of prostate cancer [J]. , 2019, 39(5): 518-.
[14]	FANG Xiao1, 2, GUO Jian-gong1, HUANG Jin-ming1, FAN Lian-cheng2. Prediction of prognostic nutritional index for the primary resistance to abiraterone and the prognosis in metastatic castration-resistant prostate cancer patients [J]. , 2019, 39(3): 316-.
[15]	CHEN Ming, FU Xiao-hong, WU Shu, WAN Yong-lin. Risk estimation of prostate cancer in patients with serum prostate-specific antigen level of 4–10 ng/mL [J]. , 2019, 39(2): 217-.